<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20161103030684N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-05-09</date_registration>
      <primary_sponsor>Yasouj University of Medical Sciences</primary_sponsor>
      <public_title>The effect of fennel powder on serum prolactin levels in nursing mothers and newborns weight gain.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of fennel powder on serum prolactin in nursing mothers and weight gain in newborns with the effect of domperidone and placebo</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-06-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/31683</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation was done with the help of lottery so that the number of people in three groups of intervention and control of the paper was inscribed with the name of the group and placed in a container and by referring each patient one paper randomly selected and the person to the group Written in the paper, Blinding description: The study is done single blind. This means that only patients who received the medication did not know.</study_design>
      <phase>3</phase>
      <hc_freetext>Comparison the effect of Foeniculum Vulgare Miller ( Fennel) on serum prolacin and newborn weight gain with the effect of Domperidone and placebo.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:After explaining the different stages of the study by the program administrators and obtaining voluntary consent from the volunteers without any costs for medicine, examination or visitation, patients of 1th  group received the capsule containing domperidone for 14 days and the level of serum prolactin before and after from the 14th day of taking the above medicine, blood samples were taken from them and blood serum was sent to the laboratory. The newborn weight at the birth time, the 14th day and the twenty-eighth day was measured using digital scales. Intervention 2: Intervention group: After explaining the different stages of the study by the program administrators and obtaining voluntary consent from the volunteers without any costs for medicine, examination or visitation, patients of 2nd group received the capsule containing fennel powder for 14 days and the level of serum prolactin before and after From the 14th day of taking the above medicine, blood samples were taken from them and blood serum was sent to the laboratory. The newborn weight at the birth time, the 14th day and the twenty-eighth day was measured using digital scales. Intervention 3: Control group: After explaining the different stages of the study by the program administrators and obtaining voluntary consent from the volunteers without any costs for medicine, examination or visitation, patients of this group received the placebo capsule for 14 days and the level of serum prolactin before and after from the 14th day of taking the above medicine, blood samples were taken from them and blood serum was sent to the laboratory. The newborn weight at the birth time, the 14th day and the twenty-eighth day was measured using digital scales.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Because the study has ended before 11.10.1397</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali keshtkari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid motahatri Blvd</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591741417</zip>
        <telephone>+98 74 3334 6078</telephone>
        <email>a_keshtkari@yahoo.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali keshtkari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid motahari Blvd</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591741417</zip>
        <telephone>+98 74 3334 6078</telephone>
        <email>a_keshtkari@yahoo.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Mothers have a newborn baby
No contraindication for breast feeding
Well baby
Not having a history of cardiovascular disease in the mother
Obtain informed and written consent of patients
Birth weight, more than 2500 grams</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>2 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:After explaining the different stages of the study by the program administrators and obtaining voluntary consent from the volunteers without any costs for medicine, examination or visitation, patients of 1th  group received the capsule containing domperidone for 14 days and the level of serum prolactin before and after from the 14th day of taking the above medicine, blood samples were taken from them and blood serum was sent to the laboratory. The newborn weight at the birth time, the 14th day and the twenty-eighth day was measured using digital scales.</i_keyword>
      <i_keyword>Intervention group: After explaining the different stages of the study by the program administrators and obtaining voluntary consent from the volunteers without any costs for medicine, examination or visitation, patients of 2nd group received the capsule containing fennel powder for 14 days and the level of serum prolactin before and after From the 14th day of taking the above medicine, blood samples were taken from them and blood serum was sent to the laboratory. The newborn weight at the birth time, the 14th day and the twenty-eighth day was measured using digital scales.</i_keyword>
      <i_keyword>Control group: After explaining the different stages of the study by the program administrators and obtaining voluntary consent from the volunteers without any costs for medicine, examination or visitation, patients of this group received the placebo capsule for 14 days and the level of serum prolactin before and after from the 14th day of taking the above medicine, blood samples were taken from them and blood serum was sent to the laboratory. The newborn weight at the birth time, the 14th day and the twenty-eighth day was measured using digital scales.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mother blood serum of prolactin.   a weight of newborn,. Timepoint: A blood sample of mothers were taken before and 14 days after using the above drugs. The birth weight, weight of the 14th  day and the 28th  day were measured. Method of measurement: blood serum  levels of prolactin were measured in the laboratory. weight measured using digital scales.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>New born weight gain. Timepoint: At birth, 14 day and 28 day after birth. Method of measurement: By digital scale.</sec_outcome>
      <sec_outcome>Change in prolactin level. Timepoint: Before taking of drug , 2 weeks later. Method of measurement: By labratory.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yasouj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-04-21</approval_date>
        <contact_name>Yasuj Research Ethic Committee</contact_name>
        <contact_address>Blvd shahid mothahari ,Yasuj Yasuj Kohgilouyeh-va-Boyrahmad Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
